Accéder au contenu
Merck

Additive cytotoxic effects of dihydroartemisinin and sodium salicylate on cancer cells.

Anticancer research (2014-07-02)
Marisa Wickerath, Narendra P Singh
RÉSUMÉ

The standard methods of chemotherapy in cancer treatment are expensive and pose serious health effects. The present study investigates an alternative chemotherapy by testing the combined treatment of two drugs on leukemia cells: dihydroartemisinin (DHA) and sodium salicylate (SS). Cells were divided into 4 treatment groups: a control, treatment with DHA-only, treatment with SS-only, and treatment with both DHA and SS. Cells were counted immediately before the addition of any reagents (0-h count), and at 24, 48, and 72 h after treatment. At low concentrations, the combination of DHA and SS significantly reduced cancer cell proliferation, although no synergistic interaction between the two drugs was found. Even without a clear synergistic interaction, the combination of DHA and SS provides a safe and affordable form of cancer treatment.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Salicylate de sodium, ReagentPlus®, ≥99.5% (titration)
Sigma-Aldrich
Salicylate de sodium, 98.0-102.0% anhydrous basis, meets USP testing specifications
Sigma-Aldrich
Salicylate de sodium, ≥99.5% (HPLC), puriss. p.a.
Sigma-Aldrich
Salicylate de sodium, puriss. p.a., reag. Ph. Eur., 99.5-101.0% (calc. to the dried substance)
Sigma-Aldrich
Salicylate de sodium, tested according to Ph. Eur.
Salicylate de sodium, European Pharmacopoeia (EP) Reference Standard